PDS Biotechnology
PDSB
21 hedge funds and large institutions have $1.43M invested in PDS Biotechnology in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0% more funds holding
Funds holding: 21 → 21 (0)
0.48% less ownership
Funds ownership: 9.84% → 9.36% (-0.48%)
17% less capital invested
Capital invested by funds: $1.72M → $1.43M (-$285K)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$81.8K |
| 2 |
AFM
Andesa Financial Management
Allentown,
Pennsylvania
|
+$47.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$15.5K |
| 4 |
IWA
Inspirion Wealth Advisors
Libertyville,
Illinois
|
+$2.28K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IGGA
Iron Gate Global Advisors
Nsl,
Utah
|
-$49K |
| 2 |
RC
RegentAtlantic Capital
Morristown,
New Jersey
|
-$7.1K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.99K |
| 5 |
EIP
Ellis Investment Partners
Berwyn,
Pennsylvania
|
-$2.85K |
PDSB Hedge Fund Activity: Q4 2019 in Review
21 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2019, worth a combined $1.43M — down 17% from $1.72M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PDSB positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $81.8K. The largest seller was Iron Gate Global Advisors, exiting entirely with an estimated $49K sold.
- 21 institutional investors held PDS Biotechnology (PDSB) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $1.43M of PDS Biotechnology stock for Q4 2019, down 17% quarter-over-quarter.
- 4 funds opened new PDS Biotechnology positions in Q4 2019 and 3 closed out, a net change of +1 holder.
- The largest PDS Biotechnology buyer in Q4 2019 was Renaissance Technologies, an estimated $81.8K added.
- The largest PDS Biotechnology seller in Q4 2019 was Iron Gate Global Advisors, an estimated $49K sold.
Based on aggregated 13F filings for Q4 2019.